Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 75

Sort by

Sort Order Select

Journal Articles

DC/Aml Fusion Cell Vaccination Administered to AML Patients Who Achieve a Complete Remission Potently Expands Leukemia Reactive T Cells and Is Associated with Durable Remissions

Blood (2015) 126 (23): 2549.

https://doi.org/10.1182/blood.V126.23.2549.2549

Published: 2015

Journal Articles

Panobinostat in Combination with Rituximab in Heavily Pretreated Diffuse Large B-Cell Lymphoma: Results of a Phase II Study

Jeffrey A. Barnes, MD PhD, Robert Allyn Redd, MS, Eric D. Jacobsen, MD, David C. Fisher, MD, Arnold S. Freedman, MD, Ephraim P Hochberg, MD, Tak Takvorian, MD, Donna Neuberg, ScD, Jeremy S. Abramson, MD

Blood (2014) 124 (21): 3055.

https://doi.org/10.1182/blood.V124.21.3055.3055

Published: 2014

Journal Articles

Superiority of Pediatric Chemotherapy over Allogeneic Hematopoietic Cell Transplantation for Philadelphia Chromosome Negative Adult ALL in First Complete Remission: A Combined Analysis of Dana-Farber ALL Consortium and CIBMTR Cohorts

Matthew D. Seftel, MDMPH FRCPC, Donna Neuberg, ScD, Mei-Jie Zhang, PhD, Hai-Lin Wang, MPH, Julie Bergeron, MD FRCPC, Stephen Couban, MD FRCPC, Daniel J. DeAngelo, MD PhD, Marcos J de Lima, MD, Steven M. Devine, MD, Mary Eapen, MBBS, Mary M. Horowitz, MD MS, Marcelo C. Pasquini, MD MS, J. Douglas Rizzo, MD, Wael Saber, MD MS, Stephen E. Sallan, Brenda M. Sandmaier, MD, Daniel J. Weisdorf, MD

Blood (2014) 124 (21): 319.

https://doi.org/10.1182/blood.V124.21.319.319

Published: 2014

Journal Articles

Risk of Intracranial Hemorrhage Associated with Enoxaparin Administration in Patients with Brain Metastasis

Jessica Donato, MD, Federico Campigotto, MS, Erika Coletti, BSN, Donna Neuberg, ScD, Griffin Weber, MD PhD, Jeffrey I. Zwicker, MD

Blood (2014) 124 (21): 348.

https://doi.org/10.1182/blood.V124.21.348.348

Published: 2014

Journal Articles

Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphomas: Final Results from a Phase 1-2 Trial

Jeremy S. Abramson, MD, Eric D. Jacobsen, MD, Robert Allyn Redd, MS, Tak Takvorian, MD, David C. Fisher, MD, Jennifer R. Brown, Joel H Schwartz, MD, James Weitzman, MD, Donna Neuberg, ScD, Jeffrey A. Barnes, MD PhD, Ephraim P Hochberg, MD

Blood (2014) 124 (21): 4423.

https://doi.org/10.1182/blood.V124.21.4423.4423

Published: 2014

Journal Articles

The Effects of Hemophilia on Socialization

Aric Parnes, MD, Christine Mitchell, MSW, Wentz Rachel, Federico Campigotto, MS, Latoya Lashley, Cathee Brunswick, Donna Neuberg, ScD, Judith C Lin, MD

Blood (2014) 124 (21): 5968.

https://doi.org/10.1182/blood.V124.21.5968.5968

Published: 2014

Journal Articles

TP53 Mutation Status Divides MDS Patients with Complex Karyotypes into Distinct Prognostic Risk Groups: Analysis of Combined Datasets from the International Working Group for MDS-Molecular Prognosis Committee

Blood (2014) 124 (21): 532.

https://doi.org/10.1182/blood.V124.21.532.532

Published: 2014

Journal Articles

Dynamics Changes in CCL3 and CCL4 Plasma Chemokine Levels in Patients with Chronic Lymhocytic Leukemia (CLL) Managed with Observation

Mariela Sivina, PhD, Lillian Werner, Laura Rassenti, PhD, William G. Wierda, MD PhD, Michael J. Keating, MD, Susan O'Brien, MD, Donna Neuberg, ScD, Thomas J. Kipps, MD PhD, Jan A. Burger, MD PhD

Blood (2014) 124 (21): 5640.

https://doi.org/10.1182/blood.V124.21.5640.5640

Published: 2014

Journal Articles

Addition of Rituximab Abrogates Ibrutinib-Induced Lymphocytosis and Promotes More Rapid Decrease in Absolute Lymphocyte Counts in Patients with Relapsed Chronic Lymphocytic Leukemia

Ekaterina Kim, MS, Lillian Werner, Michael J Keating, MBBS, William G. Wierda, MD PhD, Alessandra Ferrajoli, MD, Zeev Estrov, MD, Gracy Zacharian, Thomas J. Kipps, MD, Hagop M. Kantarjian, MD, Donna Neuberg, ScD, Susan O'Brien, MD, Jan A. Burger, MD PhD

Blood (2014) 124 (21): 1998.

https://doi.org/10.1182/blood.V124.21.1998.1998

Published: 2014

Journal Articles

Diagnostic Features and 2-Hydroxyglutarate (2-HG) Levels Among Acute Myeloid Leukemia (AML) Patients with and without Isocitrate Dehydrogenase (IDH) Mutations

Blood (2014) 124 (21): 1045.

https://doi.org/10.1182/blood.V124.21.1045.1045

Published: 2014

Journal Articles

Kinetic Measurement of Leukemia-Cell Proliferation Rate By Deuterium Labeling Predicts Time to Initial Treatment of Patients with Chronic Lymphocytic Leukemia

Blood (2014) 124 (21): 829.

https://doi.org/10.1182/blood.V124.21.829.829

Published: 2014

Journal Articles

Subclonal Driver Mutations Predict Shorter Progression Free Survival in Chronic Lymphocytic Leukemia Following First-Line Chemo(immuno)Therapy: Results from the CLL8 Trial

Blood (2014) 124 (21): 1938.

https://doi.org/10.1182/blood.V124.21.1938.1938

Published: 2014

Journal Articles

Integrated Single-Cell Detection of Genotype and Phenotype in SF3B1-Mutated Chronic Lymphocytic Leukemia Cells

Lili Wang, MD PhD, Dylan Kotliar, BA, Jean Fan, Shuqiang Li, PhD, Jonna Grimsby, Dan A. Landau, MD PhD, Jennifer R. Brown, MD PhD, Niall Lennon, Donna Neuberg, ScD, Kenneth J Livak, Catherine J. Wu, MD

Blood (2014) 124 (21): 1943.

https://doi.org/10.1182/blood.V124.21.1943.1943

Published: 2014

Journal Articles

Inhibition Of Lyn and Syk By Treatment With Dasatinib, Fludarabine, and Rituximab Correlates With Apoptosis and Clinical Response In Patients With Relapsed CLL

Philip C. Amrein, MD, Xin Kai, Carlos Donato, Jon Arnason, MD, Jennifer R. Brown, M.D., Karen K. Ballen, MD, Eyal C. Attar, MD, Amir T. Fathi, MD, Ephraim P Hochberg, MD, HyukJoo Hwang, Lillian Werner, Donna Neuberg, ScD, Shiv Pillai, MD, PhD

Blood (2013) 122 (21): 5300.

https://doi.org/10.1182/blood.V122.21.5300.5300

Published: 2013

Journal Articles

A Genetic Screen In Zebrafish Identified Dlst As a Potential Therapeutic Target For Human Acute T-Lymphoblastic Leukemia

Nicole M Anderson, PhD, Hongling Peng, MD, Daniel Helman, BS, Itrat Harrold, PhD, Takaomi Sanda, PhD, Trevor Grant, MS, Nicholas Nagykery, BS, Yasmina Samaha, Meng Le, PhD, Adam Amsterdam, PhD, Donna Neuberg, ScD, Marc R. Mansour, MD PhD FRCPath, Travis Denton, PhD, John Kanki, PhD, Anurag Singh, PhD, A. Thomas Look, MD, Hui Feng, PhD

Blood (2013) 122 (21): 1273.

https://doi.org/10.1182/blood.V122.21.1273.1273

Published: 2013

Journal Articles

Treatment of Chronic Lymphocytic Leukemia Patients with Lenalidomide Induces Down-Regulation of miR342-3p Associated with Over-Expression of Tumor Suppressor RASSF4,

Emanuela M. Ghia, PhD, Lillian Werner, Danelle F. James, M.D., Donna Neuberg, ScD, Laura G Corral, Senior, Scientist, Laura Z. Rassenti, Ph.D., Carlo M. Croce, MD, Thomas J. Kipps, M.D., Ph.D

Blood (2011) 118 (21): 3885.

https://doi.org/10.1182/blood.V118.21.3885.3885

Published: 2011

Journal Articles

Increased Dose Rituximab Followed by Maintenance Rituximab As Initial Therapy for Indolent B Cell Lymphomas: A Phase II Trial,

Jeffrey A. Barnes, MD, PhD, Kristen Stevenson, Ephraim P. Hochberg, MD, Tak Takvorian, MD, David C. Fisher, MD, Ann LaCasce, MD, Jennifer R. Brown, MD, PhD, Anuj K. Mahindra, MD, Donna Neuberg, ScD, Jeremy S. Abramson, MD

Blood (2011) 118 (21): 3716.

https://doi.org/10.1182/blood.V118.21.3716.3716

Published: 2011

Journal Articles

Molecular Ontogeny of Donor-Derived Lymphomas Occurring After Transplantation,

Oliver Weigert, MD, Nadja Kopp, Andrew A. Lane, MD, PhD, Akinori Yoda, PhD, Suzanne E. Dahlberg, PhD, Donna Neuberg, ScD, Anita Y Bahar, Bjoern Chapuy, MD, PhD, Frank Kuo, MD, PhD, Terry Haley, PhD, Timothy J Sullivan, Edward Fox, PhD, Scott J. Rodig, MD, PhD, Joseph H Antin, MD, David M Weinstock, MD

Blood (2011) 118 (21): 3671.

https://doi.org/10.1182/blood.V118.21.3671.3671

Published: 2011

Journal Articles

Relative Prognostic Significance of ZAP-70 and IGHV1-69 Expression in Chronic Lymphocytic Leukemia,

Laura Z. Rassenti, Ph.D., Emanuela M. Ghia, PhD, Lillian Werner, Donna Neuberg, ScD, George F. Widhopf, II, PhD, Thomas J. Kipps, M.D., Ph.D

Blood (2011) 118 (21): 3891.

https://doi.org/10.1182/blood.V118.21.3891.3891

Published: 2011

Journal Articles

Shifts in Intra-Clonal Dynamics Rather Than Novel Mutations Are the Main Engine Driving Tumor Evolution in Relapsed CLL

Dan-Avi Landau, MD, Petar Stojanov, Michael S Lawrence, Carrie Sougnez, Aaron McKeena, Scott Carter, Stacey Gabriel, Donna Neuberg, ScD, Nir Hacohen, Eric S Lander, Jennifer R. Brown, MD, PhD, Gad Getz, Cathy Wu

Blood (2011) 118 (21): 284.

https://doi.org/10.1182/blood.V118.21.284.284

Published: 2011

NARROW

DC/Aml Fusion Cell Vaccination Administered to AML Patients Who Achieve a Complete Remission Potently Expands Leukemia Reactive T Cells and Is Associated with Durable Remissions

Panobinostat in Combination with Rituximab in Heavily Pretreated Diffuse Large B-Cell Lymphoma: Results of a Phase II Study

Superiority of Pediatric Chemotherapy over Allogeneic Hematopoietic Cell Transplantation for Philadelphia Chromosome Negative Adult ALL in First Complete Remission: A Combined Analysis of Dana-Farber ALL Consortium and CIBMTR Cohorts

Risk of Intracranial Hemorrhage Associated with Enoxaparin Administration in Patients with Brain Metastasis

Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphomas: Final Results from a Phase 1-2 Trial

The Effects of Hemophilia on Socialization

TP53 Mutation Status Divides MDS Patients with Complex Karyotypes into Distinct Prognostic Risk Groups: Analysis of Combined Datasets from the International Working Group for MDS-Molecular Prognosis Committee

Dynamics Changes in CCL3 and CCL4 Plasma Chemokine Levels in Patients with Chronic Lymhocytic Leukemia (CLL) Managed with Observation

Addition of Rituximab Abrogates Ibrutinib-Induced Lymphocytosis and Promotes More Rapid Decrease in Absolute Lymphocyte Counts in Patients with Relapsed Chronic Lymphocytic Leukemia

Diagnostic Features and 2-Hydroxyglutarate (2-HG) Levels Among Acute Myeloid Leukemia (AML) Patients with and without Isocitrate Dehydrogenase (IDH) Mutations

Kinetic Measurement of Leukemia-Cell Proliferation Rate By Deuterium Labeling Predicts Time to Initial Treatment of Patients with Chronic Lymphocytic Leukemia

Subclonal Driver Mutations Predict Shorter Progression Free Survival in Chronic Lymphocytic Leukemia Following First-Line Chemo(immuno)Therapy: Results from the CLL8 Trial

Integrated Single-Cell Detection of Genotype and Phenotype in SF3B1-Mutated Chronic Lymphocytic Leukemia Cells

Inhibition Of Lyn and Syk By Treatment With Dasatinib, Fludarabine, and Rituximab Correlates With Apoptosis and Clinical Response In Patients With Relapsed CLL

A Genetic Screen In Zebrafish Identified Dlst As a Potential Therapeutic Target For Human Acute T-Lymphoblastic Leukemia

Treatment of Chronic Lymphocytic Leukemia Patients with Lenalidomide Induces Down-Regulation of miR342-3p Associated with Over-Expression of Tumor Suppressor RASSF4,

Increased Dose Rituximab Followed by Maintenance Rituximab As Initial Therapy for Indolent B Cell Lymphomas: A Phase II Trial,

Molecular Ontogeny of Donor-Derived Lymphomas Occurring After Transplantation,

Relative Prognostic Significance of ZAP-70 and IGHV1-69 Expression in Chronic Lymphocytic Leukemia,

Shifts in Intra-Clonal Dynamics Rather Than Novel Mutations Are the Main Engine Driving Tumor Evolution in Relapsed CLL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only